7210 Wareham Drive, Tampa, FL 33647
May 6, 2026 Medifast reports its first quarter 2026 results. According to management: “We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership advancement, and high field engagement. These are metrics that have historically been […]
Medifast Reports Q1 2026 Results Read More »
April 2, 2026 On April 1, 2026, the FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill developed by Eli Lilly for adults with obesity or overweight and at least one weight-related condition. Unlike other options, Foundayo does not require fasting or specific timing. It mimics a natural hormone to regulate appetite and,
New Eli Lilly Weight Loss Pill Approved – Foundayo Read More »
March 17, 2026 Weight Watchers reports its 2025 results yesterday. The firm’s revenues came in at $710 million, a 9.6% decline from 2024 revenues of $786 million. The company is expecting an 11% decrease in 2026 revenues, to between $620 and $635 million. 2025 Total Revenue and Adjusted EBITDA above high end of previously provided
Weight Watchers Reports Q4 & Full Year 2025 Results, 2026 Guidance Read More »
March 15, 2026 Medifast is an MLM (multilevel marketer) that sells meal replacements and diet foods, via health coaches. Their sales declined by 36% in 2025, to $386 million. Herbalife is another MLM that sells meal replacements and appetite suppressants, via health coaches. Their weight loss product sales in North America only declined by an
A Tale of Two MLM Competitors Read More »
March 12, 2026 The FDA is finally cracking down on telehealth companies marketing compounded weight loss drugs, warning them not to imply their products are FDA-approved or that they manufacture the medications. Roughly 30% of the more than 70 telehealth companies warned in the past six months rely on just four nationwide “white-label” medical groups
FDA Cracks Down on Telehealth Companies Read More »
March 4, 2026 Marketdata LLC has released a new report: “The U.S. Weight Loss Market: Status Report & 2026 Forecast” This 108-page analysis tracks the current status of ALL weight loss market segments, 2025 performance, the latest dieting trends, 15 competitor profiles, with 27 tables and charts. Some findings: The total U.S. weight loss market
U.S. Weight Loss Market Now Worth $135 Billion – New Report Read More »
Feb. 18, 2026 Medifast reported full-year and Q4 2025 results on February 17, 2026. 2025 revenues came in at $386 million – a 36% decrease from $602 million in 2024. The company employed 16,100 active earning Optavia health coaches, who had quarterly earnings of $4,664 (or $18,656 on an annual rate). “As we enter 2026,
Medifast Reports Q4 and Full Year 2025 Results Read More »
February 18, 2026 Based on the latest press release and annual report by Herbalife… The North America region reported net sales of $1.03 billion for the year ended December 31, 2025, down 2.0%. Worldwide weight management product sales declined 0.8% in 2025. North American sales, at $1.03 billion, accounted for 20.5% of total Herbalife sales.
Herbalife’s Weight Loss Sales Remained Stable in 2025 Read More »
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo
FDA Approves Novo’s Wegovy Weight Loss Pill Read More »